Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Recommendation of “Buy” from Analysts

Shattuck Labs, Inc. (NASDAQ:STTK) has been given a consensus rating of “Buy” by the twelve analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $12.7778.

STTK has been the topic of a number of research analyst reports. Needham & Company LLC raised their price target on Shattuck Labs from $14.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Citigroup upgraded Shattuck Labs from a “neutral” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Friday, June 5th. Jefferies Financial Group upgraded Shattuck Labs to an “outperform” rating and set a $7.00 price objective for the company in a research report on Friday, June 5th. Raymond James Financial began coverage on Shattuck Labs in a research note on Monday, August 24th. They set a “strong-buy” rating and a $18.00 target price for the company. Finally, Leerink Partners assumed coverage on shares of Shattuck Labs in a report on Monday, July 20th. They set an “outperform” rating and a $16.00 target price on the stock.

Insider Activity

In related news, insider Arundathy N. Pandite sold 30,000 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $7.01, for a total value of $210,300.00. Following the sale, the insider directly owned 136,219 shares of the company’s stock, valued at approximately $954,895.19. The trade was a 18.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Clay B. Siegall acquired 62,500 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The stock was bought at an average cost of $4.00 per share, for a total transaction of $250,000.00. Following the completion of the transaction, the director directly owned 318,608 shares in the company, valued at $1,274,432. This represents a 24.40% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 53,875 shares of company stock worth $379,305 over the last quarter. 8.79% of the stock is currently owned by company insiders.

Institutional Trading of Shattuck Labs

Several hedge funds and other institutional investors have recently modified their holdings of STTK. Virtu Financial LLC bought a new stake in shares of Shattuck Labs in the third quarter valued at about $38,000. Legal & General Group Plc bought a new position in shares of Shattuck Labs during the second quarter worth about $41,000. California State Teachers Retirement System bought a new position in shares of Shattuck Labs during the second quarter worth about $41,000. AQR Capital Management LLC raised its position in Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after buying an additional 31,355 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in Shattuck Labs in the 2nd quarter valued at approximately $44,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Price Performance

Shares of NASDAQ STTK opened at $6.79 on Monday. The company’s fifty day moving average is $7.16 and its 200-day moving average is $6.33. The stock has a market cap of $681.44 million, a price-to-earnings ratio of -13.31 and a beta of 1.09. Shattuck Labs has a twelve month low of $1.45 and a twelve month high of $8.33.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12). On average, research analysts anticipate that Shattuck Labs will post -0.44 EPS for the current fiscal year.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.